46 results about "Narcolepsy" patented technology

The invention relates to the technical field of narcolepsy auxiliary diagnosis, in particular to a narcolepsy patient-oriented physiological parameter monitoring method, a medium and a narcolepsy patient-oriented physiological parameter monitoring system. Segmenting the electroencephalogram signal and the electrocardiosignal in each test to obtain a plurality of electroencephalogram signal segments and a plurality of electrocardiosignal segments; obtaining the interference degree of each electrocardiosignal segment; acquiring three stages of each electrocardiosignal segment; the credible weight of the interference degree of each stage of each electrocardiosignal is obtained, and then the credibility of each stage of each electrocardiosignal is obtained; and according to the credibility and the sleep time of each stage of the electrocardiosignal, obtaining the final sleep time of the patient. According to the invention, the interference caused by inadaptation of a patient to a test environment or test equipment is reduced, and the accuracy of obtaining a sleep time result is improved.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention relates to a composition for treating K Ca 3.1 channel-mediated diseases. More specifically, the composition contains, as an active ingredient, solriamfetol which is currently used as a therapeutic agent for narcolepsy, that is, a phenylalkylcarbamate compound represented by 2-amino-3-phenylpropyl carbamate, and can inhibit the activity of K Ca 3.1 channels in cell membranes, and thus can be used for treating pharmaceutical compositions for K Ca 3.1 channel-mediated diseases such as fibrotic diseases, autoimmune diseases, and cancers.

Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention relates to potent hOX1R / hOX2R agonists, as well as their use as a medicament, in particular for the treatment of narcolepsy. In particular, the present invention relates to potent hOX1R / hOX2R agonists, with prolonged half-life and good physiochemical properties.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): # imgabs0 # wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for preventing or treating narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention aims to provide a novel compound which has an OX2R agonist activity.The present invention relates to a cyclopentane compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof has an agonist activity on OX2R and is useful as an agent for the treatment of sleep disorders involving OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to physical diseases, hypersomnia due to psychiatric disorders, hypersomnia due to drugs or substances, circadian rhythm sleep-wake disorder, insufficient sleep syndrome and long sleep) or the like.

The present invention provides heterocyclic compounds having orexin type 2 receptor agonist activity. Formula (I): JPEG2025539434000134.jpg51127 [wherein each symbol is as defined in the specification] The compound or a salt thereof has orexin type 2 receptor agonist activity and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present disclosure relates to compounds of Formula (I′):and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating orexin-2 receptor activity and may be used in the treatment of disorders in which orexin-2 receptor activity is implicated, such as narcolepsy, a hypersomnia disorder, a neurodegenerative disorder, a symptom of a rare genetic disorder, a mental health disorder, a metabolic syndrome, osteoporosis, cardiac failure, coma, or facilitating emergence from anaesthesia.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. Provided is a compound of formula (I): # imgabs0 # wherein each symbol is as described in the specification, or a salt thereof, which has orexin type 2 receptor agonist activity and is useful as an agent for preventing or treating hypersomnia.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The present invention relates to a medicament for the treatment or prevention of a disease related to the orexin receptor, especially the orexin receptor type 2, comprising a novel compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient; more specifically, the present invention relates to a medicament for the treatment or prevention of narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.

This invention provides a customized canine brain-computer interface (BCI) cap, and a customized BCI signal collection and analysis system, and methods of use of same to acquire and store EEG signals collected by the sensors in the BCI caps, to calculate defined neurological or behavioral state for the canine which find applications in detection of a hazard by the canine, such as wherein the hazard is an explosive material or a physical obstacle; or detection of a health or disease status in a human subject by the canine and in some embodiments, the neurological or behavioral state correlates with detection relates to the presence of infection, diabetes, cancer, hypoglycemia, narcolepsy, Parkinson' s disease or seizures.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present application is directed, in general, to tolerizing immune mediated particles comprising narcolepsy with cataplexy (NT1) antigens for use in treating NT1.

The invention discloses a construction method and application of a central drowsiness animal model, and belongs to the technical field of biology. The central drowsiness animal model contains a CAG-LSL-ATXN3 (Q77) DNA (deoxyribonucleic acid) molecule and an Hcrt-IRES-CreERT2 DNA molecule, the nucleotide sequence of the CAG-LSL-ATXN3 (Q77) DNA molecule is shown as SEQ ID NO: 1, and the nucleotide sequence of the Hcrt-IRES-CreERT2 DNA molecule is shown as SEQ ID NO: 2. The invention has the advantages that the animal model provided by the invention can simulate the onset of human narcolepsy 1, is beneficial to further research on the influence of orexin deficiency on brain functions and structures, and has good genetic stability.

The present invention provides a heterocyclic compound having orexin type 2 receptor agonist activity. A compound represented by formula (I): wherein each symbol is as described in the specification, or a salt thereof, useful as an agent for preventing or treating narcolepsy.

The invention discloses a deep learning-based narcolepsy automatic identification method, and relates to the technical field of narcolepsy identification. The method comprises the following steps: reading, preprocessing and segmenting EEG / ECG sleep data of multiple subjects; an electroencephalogram feature extraction module based on a Kollogov-Arnod network (KAN) is adopted; an electrocardio feature extraction module based on ResNet18 transfer learning is adopted; feature integration is realized through a feature fusion module combining an external attention mechanism and a gating fusion scheme; and inputting the fused sleep heart-brain electrical features into a classifier for classification. Through innovative application of the deep learning technology, the defects of an existing method in feature extraction, fusion and classification are overcome, the efficiency and accuracy of sleep staging and narcolepsy recognition are remarkably improved, and the method has important clinical application value.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

The present disclosure includes compositions and methods for administering to a human subject one or more orexin type 2 receptor agonists in one or more dosage forms in an amount and frequency that provides a wake-promoting blood plasma concentration of orexin type 2 receptor agonist during a portion of waking hours of a twenty-four-hour period, and a blood plasma concentration of orexin type 2 receptor agonist at or below a maximum non-awakening plasma concentration of the agonist for the remainder of the twenty-four-hour period. Also disclosed are compositions and methods for treating narcolepsy type 1 (NT1) or the symptoms of narcolepsy type 1, in a human in need of said treatment by maintaining a wake-promoting blood plasma concentration of orexin type 2 receptor agonist during a portion of waking hours of a twenty-four-hour period, and a blood plasma concentration of orexin type 2 receptor agonist at or below a maximum non-awakening plasma concentration of the agonist for the remainder of the twenty-four-hour period.